Diabetic Investor's Kliff says the number of patients who meet that condition is tiny and meaningless. Generex still needs to get Oral-lyn approved by the FDA before it can fully market the drug in the U.S.
The ADA's Robertson says the only people who worry about insulin injections are people who don't have diabetes. "Oral insulin, respiratory insulin, buccally delivered insulin are all marketing driven technologies, they are not driven by the real need of diabetes patients."
Generex shares trade for around 60 cents. I know that looks cheap but don't bother with an oral insulin delivery technology that's not going anywhere.
I had a mini debate on Twitter this week with a @jimcollins, a Sequenom (SQNM) bull who was exacerbated by what he considered to be an unjustified drop in the Sequenom's stock following Monday's quarterly conference call."I didn't hear anything on the conference call to cause a 20% drop," wrote @jimcollins. In a later tweet, he remarked, "Did people expect Harry [Hixson, Sequenom's CEO] to say, 'If we don't get a Down's Syndrome test I will commit seppuku!?'" In response to @jimcollins, I said the problem was not with the conservative and cautious comments made Monday by Hixson regarding Sequenom's effort to resurrect its gene-based Down's test, nor was it a surprise that he declined to offer financial guidance. The problem was that a lot of momentum-fueled Sequenom investors expected too much, too soon. On a related note, David N. emails, "I am a shareholder influenced from the Cantor Fitzgerald report with a $16 price target. How can that report differ so much from your report?" They don't call it sell-side research for nothing. Analysts like those at Cantor are selling you (investors) research in the hope that you (investors) will buy the firm's stock-trading services. The investment bankers who work at shops like Cantor use the research penned by the firm's analysts to woo companies to become investment-banking clients.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV